[¹⁸F]F-AraG PET药代动力学作为STING激动剂联合或不联合抗PD-1免疫治疗中T细胞激活标志物的研究
本研究为1期临床试验,纳入4例接受STING激动剂联合抗PD-1治疗的晚期实体瘤患者,在基线、治疗1周和6周进行90分钟[¹⁸F]F-AraG PET/CT扫描,采用三室模型分析肿瘤和器官的示踪剂动力学。结果显示所有肿瘤和多数器官的动力学可用双组织不可逆模型(2T3K)充分描述,且在40/55个肿瘤区域中AIC优选该模型;未观察到治疗诱导效应。静态扫描中[¹⁸F]F-AraG摄取的定量以肿瘤-血浆比值(TPR)归一化最为可靠。
要点
- 2T3K模型可充分描述[¹⁸F]F-AraG在肿瘤和多数器官中的动力学。
- 肿瘤区域中40/55以AIC优选2T3K模型。
- 未观察到治疗诱导的[¹⁸F]F-AraG摄取变化。
核心结论
- [¹⁸F]F-AraG PET在肿瘤中的摄取最佳由2T3K模型描述,且未观察到治疗诱导效应。
- 静态扫描中[¹⁸F]F-AraG摄取的定量以TPR归一化最为可靠。
研究设计与样本
- 1期临床试验纳入4例接受STING激动剂联合抗PD-1治疗的晚期实体瘤患者。
- 患者在基线、治疗1周和6周接受90分钟[¹⁸F]F-AraG PET/CT扫描。
- 采用三室模型对肿瘤和器官的示踪剂动力学进行建模,基于AIC、拟合质量视觉评估和动力学参数可靠性选择模型。
- 使用散点图评估主要动力学指标(Ki、VT)与简化摄取指标(SUV、TBR、TPR)的关系。
- 试验注册号NCT03843359,注册日期2019年2月14日。
主要发现
- 所有肿瘤和多数器官的动力学可用2T3K模型充分描述。
- 基于AIC,40/55个肿瘤区域优选2T3K模型。
- 主要动力学参数与简化摄取指标之间在所有指标上呈一致线性趋势。
- SUV和TBR存在患者特异性偏倚,使用TPR时可校正。
- 未观察到治疗诱导的[¹⁸F]F-AraG摄取变化。
关键数值与推荐
- 2T3K模型在40/55个肿瘤区域中基于AIC被选为优选模型。
- 静态扫描定量推荐使用TPR归一化以校正SUV和TBR的患者特异性偏倚。
临床怎么用
- 静态[¹⁸F]F-AraG PET扫描定量分析时,优先使用TPR而非SUV或TBR进行归一化。
- 动力学建模可选用2T3K模型描述肿瘤和多数器官的摄取。
局限性
- 样本量仅4例患者,结论需更大样本验证。
- 未观察到治疗诱导效应,可能受样本量小限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an urgent need for clinical biomarkers to monitor the mechanistic efficacy of immunotherapy in oncology. The [18F]F-AraG tracer, developed to image activated T cells, may provide the means to establish such a biomarker. This study extends previously reported pharmacokinetic findings in untreated NSCLC across additional tumor types undergoing immunotherapy, and examines [18F]F-AraG kinetics in various organs. Four patients with advanced solid tumors were included in this phase 1 trial investigating a stimulator of interferon genes agonist with anti-programmed cell death protein 1. Patients underwent a 90 min [18F]F-AraG PET/CT scan at baseline, one week and six weeks on-treatment. The tracer kinetics in tumors and organs were modeled using three compartment models. Model selection was based on the Akaike information criterion (AIC), visual assessment of the fit quality, and the reliability of estimated kinetic parameters. The relationship between the primary kinetic measures (influx rate (Ki), volume of distribution (VT)) and the simplified uptake metrics (standardized uptake values (SUV), tumor-to-blood ratio (TBR) and tumor-to-plasma ratio (TPR)) were evaluated using scatter plots. RESULTS: The kinetics of all tumors and most organs were adequately described with the two-tissue irreversible model (2T3K), which was identified as the preferred model based on the AIC in 40/55 tumor regions. For most organs, the 2T3K model was selected. We observed a consistent linear trend across all metrics for the relationship between primary kinetic parameters and simplified uptake metrics. However, a patient-specific bias can be observed for SUV and TBR, which was corrected for when using the TPR. CONCLUSION: This study confirms that [18F]F-AraG PET uptake in tumors is best described by a 2T3K model, with no treatment-induced effects observed. Quantification of [18F]F-AraG uptake in static scans is most reliable when normalized using the TPR. TRIAL REGISTRATION: ClinicalTrials.gov at 14 February 2019, NCT03843359, https//clinicaltrials.gov/study/NCT03843359.
引用
- Pouw JEE, Stavenga M, Wijngaarden JE, et al. PET pharmacokinetics of [¹⁸F]F-AraG as a marker of T cell activation during immunotherapy with a STING agonist with and without anti-PD-1. EJNMMI Res. 2026. PMID: 42867758. doi:10.1186/s13550-026-01503-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。